Preclinical data showing efficacy of AEF0217 in a mouse genetic model of autism spectrum disorder presented at the 2nd European Conference on Phelan-McDermid Syndrome
The 2nd European Conference on Phelan-McDermid Syndrome was held in Madrid from 9 to 11 June 2023
Pier Vincenzo Piazza, Managing Director of Aelis Farma, declares: “The preclinical data obtained by Dr. Betancur’s group have aroused great interest from the scientific community and they encourage us to evaluate, in addition to the ongoing program in trisomy 21, the feasibility of developing AEF0217 in this new indication. More generally, they suggest that AEF0217 could also help patients who suffer from autism spectrum disorder, potentially considerably opening up the fields of application of our second drug candidate. »
To receive all of AELIS FARMA’s financial information in real time, send a request by e-mail to [email protected]. Your registration will be immediate.